<DOC>
	<DOCNO>NCT01515228</DOCNO>
	<brief_summary>The purpose study examine safety effectiveness coronary stenting Cilotax stent compare Xience Prime stent treatment diabetic patient .</brief_summary>
	<brief_title>Comparison Cilotax Stent Everolimus -Eluting Stent With Diabetes Mellitus ( ESSENCE-DM III )</brief_title>
	<detailed_description>Prospective , randomized multi-center trial 300 patient enrol 7 center Korea . Following angiography , diabetic patient significant diameter stenosis &gt; 50 % visual estimation document myocardial ischemia symptom angina , eligible stenting without exclusion criterion randomize 1:1 : ) Cilotax stent vs. b ) Xience Prime stent . All patient follow least 1 year . Angiographic follow-up 9-months routinely recommend .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Clinical : Diabetic patient active treatment ( oral agent insulin ) Patients angina documented ischemia patient document silent ischemia Patients eligible intracoronary stenting Age &gt; 20 year , &lt; 75 year Angiographic : De novo lesion Percent diameter stenosis ≥ 50 % Reference vessel size ≥ 2.5 mm visual estimation 1 . History bleed diathesis coagulopathy 2 . Pregnant state 3 . Known hypersensitivity contraindication contrast agent heparin 4 . Limited lifeexpectancy ( less 1 year ) 5 . STelevation acute myocardial infraction require primary stenting 6 . Characteristics lesion : left main disease , instent restenosis , graft vessel 7 . Hematological disease ( Neutropenia &lt; 3000/mm3 ) , Thrombocytopenia &lt; 100,000/mm3 ) 8 . Hepatic dysfunction , liver enzyme ( ALT AST ) elevation ≥ 3times normal 9 . Renal dysfunction , creatinine ≥ 2.0mg/dL 10 . Contraindication aspirin , clopidogrel cilostazol 11 . Contraindication Paclitaxel everolimus 12 . Left ventricular ejection fraction &lt; 30 % 13 . Patients actively participate another drug device investigational study , complete primary endpoint followup period 14 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment example : oxygen dependent chronic obstructive pulmonary disease , active hepatitis severe liver function kidney disease )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>require drug elute stent</keyword>
</DOC>